These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32566431)

  • 21. Effect of delay in adjuvant oxaliplatin-based chemotherapy for stage III colon cancer.
    Peixoto RD; Kumar A; Speers C; Renouf D; Kennecke HF; Lim HJ; Cheung WY; Melosky B; Gill S
    Clin Colorectal Cancer; 2015 Mar; 14(1):25-30. PubMed ID: 25465343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data.
    Lin PC; Lee MY; Wang WS; Yen CC; Chao TC; Hsiao LT; Yang MH; Chen PM; Lin KP; Chiou TJ
    Support Care Cancer; 2006 May; 14(5):484-7. PubMed ID: 16450089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant chemotherapy with oxaliplatin, in combination with fluorouracil plus leucovorin prolongs disease-free survival, but causes more adverse events in people with stage II or III colon cancer Abstracted from: Andre T, Boni C, Mounedji-Boudiaf L, et al. Multicenter international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.
    Cancer Treat Rev; 2004 Dec; 30(8):711-3. PubMed ID: 15541581
    [No Abstract]   [Full Text] [Related]  

  • 24. Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer.
    Panchal JM; Lairson DR; Chan W; Du XL
    Clin Colorectal Cancer; 2013 Jun; 12(2):113-21. PubMed ID: 23137529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. von Willebrand Factor-Rich Platelet Thrombi in the Liver Cause Sinusoidal Obstruction Syndrome following Oxaliplatin-Based Chemotherapy.
    Nishigori N; Matsumoto M; Koyama F; Hayakawa M; Hatakeyayama K; Ko S; Fujimura Y; Nakajima Y
    PLoS One; 2015; 10(11):e0143136. PubMed ID: 26580395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
    Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
    Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant chemotherapy for high-risk stage II and stage III colon cancer: timing of initiation and optimal duration.
    Paolo M Cruz J; George C Pales C; Min Kim K; Wan Kim Y
    J BUON; 2018; 23(3):568-573. PubMed ID: 30003720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial.
    Klaver CEL; Wisselink DD; Punt CJA; Snaebjornsson P; Crezee J; Aalbers AGJ; Brandt A; Bremers AJA; Burger JWA; Fabry HFJ; Ferenschild F; Festen S; van Grevenstein WMU; Hemmer PHJ; de Hingh IHJT; Kok NFM; Musters GD; Schoonderwoerd L; Tuynman JB; van de Ven AWH; van Westreenen HL; Wiezer MJ; Zimmerman DDE; van Zweeden AA; Dijkgraaf MGW; Tanis PJ;
    Lancet Gastroenterol Hepatol; 2019 Oct; 4(10):761-770. PubMed ID: 31371228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
    Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
    Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Review of High-Risk Factors and Adjuvant Chemotherapy Indication in T4-pStage Ⅱ Colon Cancer].
    Hirokawa T; Nakai N; Maeda A; Takasu K; Yanagita T; Suzuki T; Maeda Y; Shiga K; Hara M; Ogawa R; Takahashi H; Matsuo Y; Takiguchi S
    Gan To Kagaku Ryoho; 2019 Aug; 46(8):1330-1333. PubMed ID: 31501382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Fluoropyrimidines with oxaliplatin(L-OHP) as an adjuvant chemotherapy for Stage III colon cancer].
    Miyake Y; Ikeda K; Osawa H; Nagase H; Hoshi M; Doi T; Makari Y; Oshima S; Iijima S; Kurokawa E; Kikkawa N
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):2161-3. PubMed ID: 23268010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant chemotherapy for colon cancer: the difference between Japanese and western strategies.
    Tsuji Y; Sugihara K
    Expert Opin Pharmacother; 2016; 17(6):783-90. PubMed ID: 26799310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study.
    Tougeron D; Mouillet G; Trouilloud I; Lecomte T; Coriat R; Aparicio T; Des Guetz G; Lécaille C; Artru P; Sickersen G; Cauchin E; Sefrioui D; Boussaha T; Ferru A; Matysiak-Budnik T; Silvain C; Karayan-Tapon L; Pagès JC; Vernerey D; Bonnetain F; Michel P; Taïeb J; Zaanan A
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26839356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant Chemotherapy for Stage II and III Colon Cancer Following Complete Resection: A Cancer Care Ontario Systematic Review.
    Meyers BM; Cosby R; Quereshy F; Jonker D
    Clin Oncol (R Coll Radiol); 2017 Jul; 29(7):459-465. PubMed ID: 28341242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience.
    Peng J; Li W; Zhang R; Lin J; Tang J; Wen Y; Lu Z; Wu X; Pan Z
    Cancer Commun (Lond); 2019 Oct; 39(1):59. PubMed ID: 31619288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A case of portal hypertension after 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy].
    Ogata H; Gushima T; Maruoka S; Takasaki S; Tanaka R; Matsuura T; Aishima S; Takahashi K
    Nihon Shokakibyo Gakkai Zasshi; 2013 Dec; 110(12):2119-26. PubMed ID: 24305101
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Noninferiority of three months versus six months of oxaliplatin-based adjuvant chemotherapy for resected colon cancer. How should IDEA findings affect clinical practice?
    Formica V; Zaniboni A; Loupakis F; Roselli M
    Int J Cancer; 2018 Nov; 143(10):2342-2350. PubMed ID: 29873066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer: A Systematic Review and Meta-analysis.
    Boyne DJ; Cuthbert CA; O'Sullivan DE; Sajobi TT; Hilsden RJ; Friedenreich CM; Cheung WY; Brenner DR
    JAMA Netw Open; 2019 May; 2(5):e194154. PubMed ID: 31099875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Adjuvant Treatment of Stage III Colon Cancer: Might Less Be More?
    Lee JJ; Chu E
    Oncology (Williston Park); 2018 Sep; 32(9):437-42, 444. PubMed ID: 30248163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Should adjuvant chemotherapy be recommended to a 75-year-old woman with deficient mismatch repair (dMMR) gene product expression seen in a stage II colon adenocarcinoma with lymphovascular invasion?
    Sorscher S
    Curr Probl Cancer; 2018 Nov; 42(6):601-604. PubMed ID: 30119912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.